A breakthrough active immunotherapy for the treatment of osteoarthritis

Project Information

Anti-IL-6

Grant agreement ID: 101145362

DOI

10.3030/101145362

Project closed

EC signature date 23 February 2024

Start date 1 March 2024

End date 28 February 2026

Funded under

• The European Innovation Council (EIC)

Total cost

€ 3 965 000,00

EU contribution

€ 2 499 999,00

Coordinated by

PEPTINOV
France

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (1)

Safety and immunogenicity of PPV-06, an active anti-IL-6 immunotherapy targeting low-grade inflammation against knee osteoarthritis: a randomized, double-blind, placebo-controlled, clinical phase 1 study

Author(s): François Rannou, Lucille Desallais, Christelle Nguyen, Camille Daste, Quentin Kirren, Marie-Martine Lefevre-Colau, Odile Launay, Hadley Mouhsine, Barbara Ruiz, Gabriel Moreau, Florent Langenfeld, Edita Dolimier, Hervé Do, René Azoulai, Francis Berenbaum, Marie-Christophe Boissier, Jean-Pierre Salles, Jean-François Zagury
Published in: Nature Communications, Issue 16, 2025, ISSN 2041-1723
Publisher: Springer Science and Business Media LLC
DOI: 10.1038/S41467-025-64710-6